Long-term consequences of a single treatment of mice with an ultra-low dose of Δ9-tetrahydrocannabinol (THC)

Behavioural Brain Research

Volumn 206, Issue 2, 2010, Pages 245-253

  Amal, Haitham ^a   Fridman Rozevich, Lilach ^a   Senn, Roey ^a   Strelnikov, Anastasia ^a   Gafni, Mikhal ^a   Keren, Ora ^a   Sarne, Yosef ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

9 Tetrahydrocannabinol (THC); Cannabinoid drugs; Cognitive deficits; Extracellular regulated kinase (ERK); Learning and memory; Marijuana; Recognition tests; Spatial learning tests

Indexed keywords

DRONABINOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CEREBELLUM; COGNITIVE DEFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; LEARNING; LONG TERM EXPOSURE; MALE; MAZE TEST; MENTAL PERFORMANCE; MOTIVATION; MOUSE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PSYCHOLOGIC TEST; REGULATORY MECHANISM; SPATIAL DISCRIMINATION; VISUAL MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CEREBELLUM; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MALE; MAZE LEARNING; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; PHOSPHORYLATION; PSYCHOTROPIC DRUGS; RECOGNITION (PSYCHOLOGY); SPATIAL BEHAVIOR; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 70350345257     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.09.021     Document Type: Article

References (74)

1. Agell N., Bachs O., Rocamora N., and Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal 14 (2002) 649-654
2. Arnone D., Barrick T.R., Chengappa S., Mackay C.E., Clark C.A., and Abou-Saleh M.T. Corpus callosum damage in heavy marijuana use: preliminary evidence from diffusion tensor tractography and tract-based spatial statistics. Neuroimage 41 (2008) 1067-1074
3. Baker D., Pryce G., Giovannoni G., and Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol 2 (2003) 291-298
4. Block R.I. Does heavy marijuana use impair human cognition and brain function?. JAMA 275 (1996) 560-561
5. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 Pt 2 (1995) 637-641
6. Dere E., Huston J.P., and De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31 (2007) 673-704
7. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., et al. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci 23 (2003) 2371-2382
8. Egerton A., Allison C., Brett R.R., and Pratt J.A. Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 30 (2006) 680-695
9. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 142 (1999) 295-301
10. Fehr K.A., Kalant H., and LeBlanc A.E. Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science 192 (1976) 1249-1251
11. Fletcher J.M., Page J.B., Francis D.J., Copeland K., Naus M.J., Davis C.M., et al. Cognitive correlates of long-term cannabis use in Costa Rican men. Arch Gen Psychiatry 53 (1996) 1051-1057
12. Fried P.A., Watkinson B., and Gray R. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol Teratol 27 (2005) 231-239
13. Frisone D.F., Frye C.A., and Zimmerberg B. Social isolation stress during the third week of life has age-dependent effects on spatial learning in rats. Behav Brain Res 128 (2002) 153-160
14. Galve-Roperh I., Rueda D., Gomez del Pulgar T., Velasco G., and Guzman M. Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. Mol Pharmacol 62 (2002) 1385-1392
15. Gidday J.M. Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci 7 (2006) 437-448
16. Golub M.S., Sassenrath E.N., and Chapman L.F. An analysis of altered attention in monkeys exposed to delta-9-tetrahydrocannabinol during development. Neurobehav Toxicol Teratol 4 (1982) 469-472
17. Grant I., Gonzalez R., Carey C.L., Natarajan L., and Wolfson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc 9 (2003) 679-689
18. Grant I., Rochford J., Fleming T., and Stunkard A. A neuropsychological assessment of the effects of moderate marihuana use. J Nerv Mental Dis 156 (1973) 278-280
19. Guzman M. Neurons on cannabinoids: dead or alive?. Br J Pharmacol 140 (2003) 439-440
20. Guzman M., Sanchez C., and Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 95 (2002) 175-184
21. Guzman M., Sanchez C., and Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J Mol Med 78 (2001) 613-625
22. Hoppenbrouwers S.S., Schutter D.J., Fitzgerald P.B., Chen R., and Daskalakis Z.J. The role of the cerebellum in the pathophysiology and treatment of neuropsychiatric disorders: a review. Brain Res Rev 59 (2008) 185-200
23. Ito M. Control of mental activities by internal models in the cerebellum. Nat Rev Neurosci 9 (2008) 304-313
24. Ivanov A., Pellegrino C., Rama S., Dumalska I., Salyha Y., Ben-Ari Y., et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol 572 (2006) 789-798
25. Jager G., Kahn R.S., Van Den Brink W., Van Ree J.M., and Ramsey N.F. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 185 (2006) 358-368
26. Kanayama G., Rogowska J., Pope H.G., Gruber S.A., and Yurgelun-Todd D.A. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology 176 (2004) 239-247
27. Karanian D.A., Karim S.L., Wood J.T., Williams J.S., Lin S., Makriyannis A., et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther 322 (2007) 1059-1066
28. Landfield P.W., Cadwallader L.B., and Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res 443 (1988) 47-62
29. Lawston J., Borella A., Robinson J.K., and Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55, 212-2. Brain Res 877 (2000) 407-410
30. Liou A.K., Clark R.S., Henshall D.C., Yin X.M., and Chen J. To die or not to die for neurons in ischemia, traumatic brain injury and epilepsy: a review on the stress-activated signaling pathways and apoptotic pathways. Prog Neurobiol 69 (2003) 103-142
31. Lyketsos C.G., Garrett E., Liang K.Y., and Anthony J.C. Cannabis use and cognitive decline in persons under 65 years of age. Am J Epidemiol 149 (1999) 794-800
32. Mackie K., and Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89 (1992) 3825-3829
33. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
34. Matochik J.A., Eldreth D.A., Cadet J.L., and Bolla K.I. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend 77 (2005) 23-30
35. McHale S., and Hunt N. Executive function deficits in short-term abstinent cannabis users. Hum Psychopharmacol 23 (2008) 409-415
36. Mechoulam R., Panikashvili D., and Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8 (2002) 58-61
37. Mereu G., Fa M., Ferraro L., Cagiano R., Antonelli T., Tattoli M., et al. Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci USA 100 (2003) 4915-4920
38. Moranta D., Esteban S., and Garcia-Sevilla J.A. Acute, chronic and withdrawal effects of the cannabinoid receptor agonist WIN55212-2 on the sequential activation of MAPK/Raf-MEK-ERK signaling in the rat cerebral frontal cortex: short-term regulation by intrinsic and extrinsic pathways. J Neurosci Res 85 (2007) 656-667
39. Mulholland P.J., and Prendergast M.A. Transection of intrinsic polysynaptic pathways reduces N-methyl-d-aspartate neurotoxicity in hippocampal slice cultures. Neurosci Res 46 (2003) 369-376
40. Murray B., Alessandrini A., Cole A.J., Yee A.G., and Furshpan E.J. Inhibition of the p44/42 MAP kinase pathway protects hippocampal neurons in a cell-culture model of seizure activity. Proc Natl Acad Sci USA 95 (1998) 11975-11980
41. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19 (1999) 2987-2995
42. O'Shea M., and Mallet P.E. Impaired learning in adulthood following neonatal delta9-THC exposure. Behav Pharmacol 16 (2005) 455-461
43. O'Shea M., McGregor I.S., and Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20 (2006) 611-621
44. 2+ concentration in rats. Neurosci Lett 140 (1992) 55-58
45. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413 (2001) 527-531
46. Pope Jr. H.G., and Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 275 (1996) 521-527
47. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., et al. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33 (2008) 1113-1126
48. Rubino T., Forlani G., Vigano D., Zippel R., and Parolaro D. Modulation of extracellular signal-regulated kinases cascade by chronic delta 9-tetrahydrocannabinol treatment. Mol Cell Neurosci 25 (2004) 355-362
49. Rubino T., Realini N., Braida D., Guidi S., Capurro V., Vigano D., et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus (2009)
50. Rubovitch V., Gafni M., and Sarne Y. The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101 (2002) 93-102
51. 2+ flux into N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 120 (2004) 138-144
52. Runden E., Seglen P.O., Haug F.M., Ottersen O.P., Wieloch T., Shamloo M., et al. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. J Neurosci 18 (1998) 7296-7305
53. Sanchez C., Galve-Roperh I., Rueda D., and Guzman M. Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol Pharmacol 54 (1998) 834-843
54. Sarne Y., and Keren O. Are cannabinoid drugs neurotoxic or neuroprotective?. Med Hypotheses 63 (2004) 187-192
55. Sarne Y., and Mechoulam R. Cannabinoids: between Neuroprotection and Neurotoxicity. Curr Drug Targets-CNS Neurol Disord 4 (2005) 677-684
56. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol Biochem Behav 40 (1991) 671-676
57. Scallet A.C., Uemura E., Andrews A., Ali S.F., McMillan D.E., Paule M.G., et al. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436 (1987) 193-198
58. Senn R., Keren O., Hefetz A., and Sarne Y. Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice. Pharmacol Biochem Behav 88 (2008) 230-237
59. Shen M., Piser T.M., Seybold V.S., and Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16 (1996) 4322-4334
60. Solowij N., Michie P.T., and Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 37 (1995) 731-739
61. Solowij N., Michie P.T., and Fox A.M. Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40 (1991) 683-688
62. Solowij N., Stephens R.S., Roffman R.A., Babor T., Kadden R., Miller M., et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 287 (2002) 1123-1131
63. Soriano F.X., Papadia S., Hofmann F., Hardingham N.R., Bading H., and Hardingham G.E. Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci 26 (2006) 4509-4518
64. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 275 (2000) 12200-12206
65. Stiglick A., and Kalant H. Behavioral effects of prolonged administration of delta 9-tetrahydrocannabinol in the rat. Psychopharmacology (Berl) 80 (1983) 325-330
66. Stiglick A., and Kalant H. Learning impairment in the radial-arm maze following prolonged cannabis treatment in rats. Psychopharmacology (Berl) 77 (1982) 117-123
67. Stiglick A., and Kalant H. Residual effects of prolonged cannabis administration on exploration and DRL performance in rats. Psychopharmacology (Berl) 77 (1982) 124-128
68. Tselnicker I., Keren O., Hefetz A., Pick C.G., and Sarne Y. A single low dose of tetrahydrocannabinol induces long-term cognitive deficits. Neurosci Lett 411 (2007) 108-111
69. van der Stelt M., and Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromol Med 7 (2005) 37-50
70. van der Stelt M., Veldhuis W.B., Bar P.R., Veldink G.A., Vliegenthart J.F., and Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21 (2001) 6475-6479
71. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bar P.R., et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21 (2001) 8765-8771
72. Verrico C.D., Jentsch J.D., Roth R.H., and Taylor J.R. Repeated, intermittent delta(9)-tetrahydrocannabinol administration to rats impairs acquisition and performance of a test of visuospatial divided attention. Neuropsychopharmacology 29 (2004) 522-529
73. Whishaw I.Q., and Tomie J.A. Of mice and mazes: similarities between mice and rats on dry land but not water mazes. Physiol Behav 60 (1996) 1191-1197
74. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., et al. Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry 65 (2008) 694-701